UBS分析师使用了三年期反向折现现金流 (DCF)模型来支撑目标价。基于该模型，当前股价暗示2024年至2027年的收入复合年增长率 (CAGR)为9%，这与UBS预估的-1%收入CAGR形成对比。

UBS认为,在NASDAQ上市的Tyra Biosciences有潜力凭借其口服治疗方案引领市场。作为一种选择性FGFR3抑制剂,TYRA-300预计将比同时影响FGFR1、2和4的其他FGFR抑制剂提供更好的疗效和安全性。UBS分析师认为,TYRA-300在肿瘤学和生长障碍方面的长期机会比当前市场估值所反映的更为重要。

UBS analysts upgrade Bank of America (BAC) to Buy from Neutral and lift their price target to $53 from $43. The analysts ...

Digital Realty shares rose 32% last year as demand for artificial intelligence capacity soared but data center space remained ...

Financial analysts from HSBC and UBS upgrade Bank of America to Buy, citing favorable earnings outlook and stock valuation in ...

Nicolas Gaudois, head of Asia-Pacific technology research at UBS, discusses the main growth drivers for the names under its ...

UBS Group AG shares rose the most in two months as analysts at BNP Paribas Exane recommended buying on expectations the Swiss ...

智通财经APP获悉，瑞银(UBS.US)股价创下两个月来最大涨幅，此前法国巴黎银行证券部分析师Jeremy ...

智通财经APP获悉，周五， 瑞银 (UBS.US)美股盘前涨逾4%，报31.57美元。消息面上，此前法国巴黎银行证券部分析师Jeremy Sigee预期这家瑞士银行将增加 股票回购 ...

Investing.com -- Shares of Boliden (ST: BOL) rose over 3% on Tuesday following an upgrade to a 'neutral' rating by analysts ...

According to UBS's Marcelli, there is a small chance for a “tariff shock” bear case. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

State-driven curbs on new facilities and production cuts by the biggest players will help rectify imbalance, analyst says.